163803-58-5

Basic information

• Product Name: Benzenesulfonamide, 4-[(dicyanomethylene)hydrazino]-N-2-thiazolyl-
• CAS NO: 163803-58-5
• Molecular Formula: C12H8N6O2S2
• Molecular Weight: 332.367
• Mol File: 163803-58-5.mol
• Article Data: 4

Chemical Properties

• CAS DataBase Reference: Benzenesulfonamide, 4-[(dicyanomethylene)hydrazino]-N-2-thiazolyl-(CAS DataBase Reference)
• NIST Chemistry Reference: Benzenesulfonamide, 4-[(dicyanomethylene)hydrazino]-N-2-thiazolyl-(163803-58-5)
• EPA Substance Registry System: Benzenesulfonamide, 4-[(dicyanomethylene)hydrazino]-N-2-thiazolyl-(163803-58-5)

Safety Data

• Hazardous Substances Data: 163803-58-5(Hazardous Substances Data)

Upstream product

• 109-77-3 malononitrile 
• 65446-43-7 4-hydrazinyl-N-(thiazol-2-yl)benzenesulfonamide 
• 72-14-0 Sulfathiazole 

Relevant articles and documents

Synthesis and antimicrobial evaluation of some new pyrazolo[1,5-a]pyrimidine and pyrazolo[1,5-c]triazine derivatives containing sulfathiazole moiety

A number of important fused heterocyclic systems have been prepared by the reaction of 4-((3,5-diamino-1H-pyra-zol-4-yl)-diazenyl)-N-(thiazol-2-yl)-benzenesulfonamide with some bifunctional nucleophiles such as ethyl acetoacetate, acetylacetone or arylide

4-Arylazo-3,5-diamino-1H-pyrazole CDK inhibitors: SAR study, crystal structure in complex with CDK2, selectivity, and cellular effects

In a routine screening of our small-molecule compound collection we recently identified 4-arylazo-3,5-diamino-1H-pyrazoles as a novel group of ATP antagonists with moderate potency against CDK2-cyclin E. A preliminary SAR study based on 35 analogues suggests ways in which the pharmacophore could be further optimized, for example, via substitutions in the 4-aryl ring. Enzyme kinetics studies with the lead compound and X-ray crystallography of an inhibitor-CDK2 complex demonstrated that its mode of inhibition is competitive. Functional kinase assays confirmed the selectivity toward CDKs, with a preference for CDK9-cyclin T1. The most potent inhibitor, 4-[(3,5-diamino-1H-pyrazol-4-yl) diazenyl]phenol 31b (CAN508), reduced the frequency of S-phase cells of the cancer cell line HT-29 in antiproliferation assays. Further observed cellular effects included decreased phosphorylation of the retinoblastoma protein and the C-terminal domain of RNA polymerase II, inhibition of mRNA synthesis, and induction of the tumor suppressor protein p53, all of which are consistent with inhibition of CDK9.